Formulation and Evaluation of Proniosome Based Drug Delivery System of the Antifungal Drug Clotrimazole
DOI:
https://doi.org/10.37285/ijpsn.2013.6.1.4Abstract
In the present study proniosomal gel of clotrimazole was formulated by using lecithin, cholesterol as encapsulating agents, nonionic surfactants Span and Tween with different grades. Evaluation of proniosomal gels for pH, vesicle size analysis, encapsulation efficiency, drug diffusion profiles, ex-vivo skin permeation and ex-vivo drug deposition studies on guinea pig skin, irritation test on rabbit and stability studies was performed. The preliminary compatibility studies revealed that there were no interactions between clotrimazole and excipients which was evident from FTIR and DSC studies. The physical characteristics of proniosomal gels were found to be within the acceptable limits. The vesicle size was found to be in the range 5.25-15.23μm. The proniosomes were spherical and homogenous in structure when observed under optical microscopy. The ex-vivo skin permeation and ex-vivo drug deposition studies showed the drug release from formulations F3, F4 and marketed formulation was 48.60%, 36.9% and 27.48 % respectively and the percent of clotrimazole deposited in skin after 24 h was found to be 35.7%, 43.6% and 15.17% for formulation F3, F4 and marketed formulation respectively. The release from the proniosomal gel was prolonged when compared to conventional formulation and showed a two fold increase in the drug deposition in the skin compared to conventional cream. No obvious erythema, edema or inflammation was observed on rabbits’ skin after one week of application of the selected formulation. Results of antifungal studies revealed that the developed proniosomal gel is more efficient when compared with the marketed formulation. The stability studies showed that proniosomal gels were stable at 5±3°C and 25±2°C. The above results indicated that the proniosomal gels of clotrimazole could be formulated for sustained release.
Downloads
Metrics
Keywords:
Clotrimazole, Proniosomal gel, Lecithin, Cholesterol, Ex-vivo studyDownloads
Published
How to Cite
Issue
Section
References
Aggarwal D and Kaur IP (2005). “Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system”. International Journal of Pharmaceutics 290: 155-9.
Anantnarayan (1997). “Text Book of Microbiology”, 5th Edn., Orient Longman Ltd., Chennai: 369-71.
Azarbayjani AF, Tan EH, Chan YW and Chan SY(2009). Transdermal delivery of haloperidol by proniosomal formulations with non-ionic surfactants. Biol. Pharm. Bull 32: 1453-8.
Escribano E, Calpena AC, Queralt, J, Obach R and Doménech J (2003). Assessment of diclofenac permeation with different formulations: anti-inflammatory study of a selected formula. Eur. J. Pharm. Sci 19: 203–10.
Fang JY, Yu SY, Wu PC, Huang YB and Tsai YH (2001). In-vitro skin permeation of estradiol from various proniosomes formulation. International Journal of Pharmaceutics 215: 91-9.
Hu C and Rhodes DG(1999). Proniosomes: A Novel Drug Carrier Preparation. International Journal of Pharmaceutics 185: 23-5.
Jain NK, Vora B and Khopade AJ (1998). Proniosome based transdermal delivery of levonorgestrel for effective contraception. J Control Rel 54: 149-5.
Kakkar R, Rao R, Dahiya NK and Nanda S (2011). Formulation and characterisation of valsartan proniosomes Maejo Int. J. Sci. Technol 5: 146-148.
Mokhtar M, Sammour OA, Hammad MA and Megrab NA (2008). Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes. International Journal of Pharmaceutics 361: 104-1.
Perrett S, Golding M and Willams WP (1991). A simple method for the preparation of liposomes for pharmaceutical application and characterization of liposomes. J. Pharm. Pharmacol 43: 154-1.
Shamsheer AS, Sabareesh M, Khan PR, Sai KP and Sudheer B (2011). Formulation and Evaluation of Lisinopril Dihydrate Transdermal Proniosomal Gels. J App Pharm Sci 1: 181-5.
Sweetman SC (2007). In: Martindale, editor. The Complete Drug Reference. 35 ed. London: Pharmaceutical Press;. p. 477.
Van-Abbé NJ, Nicholas P and Boon E (1975). Exaggerated exposure in topical irritancy and sensitization testing. J. Soc. Cosmet. Chem 26: 173.
WHO (2006). Draft regional guidelines on stability testing of active substances and pharmaceutical products, 17.